Literature DB >> 16709036

Recurrent glioblastoma multiforme: a review of natural history and management options.

Lewis C Hou1, Anand Veeravagu, Andrew R Hsu, Victor C K Tse.   

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors, with a grim prognosis despite maximal treatment. Advancements in the past decades have not significantly increased the overall survival of patients with this disease. The recurrence of GBM is inevitable, its management often unclear and case dependent. In this report, the authors summarize the current literature regarding the natural history, surveillance algorithms, and treatment options of recurrent GBM. Furthermore, they provide brief discussions regarding current novel efforts in basic and clinical research. They conclude that although recurrent GBM remains a fatal disease, the literature suggests that a subset of patients may benefit from maximal treatment efforts. Nevertheless, further research effort in all aspects of GBM diagnosis and treatment remains essential to improve the overall prognosis of this disease.

Entities:  

Mesh:

Year:  2006        PMID: 16709036     DOI: 10.3171/foc.2006.20.4.2

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  105 in total

1.  A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.

Authors:  Xishan Chen; Lingyu Tai; Jie Gao; Jianchang Qian; Mingfei Zhang; Beibei Li; Cao Xie; Linwei Lu; Wuyuan Lu; Weiyue Lu
Journal:  J Control Release       Date:  2015-09-30       Impact factor: 9.776

2.  Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.

Authors:  Byron C Masi; Betty M Tyler; Hansen Bow; Robert T Wicks; Yuan Xue; Henry Brem; Robert Langer; Michael J Cima
Journal:  Biomaterials       Date:  2012-05-14       Impact factor: 12.479

3.  Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET.

Authors:  M Wank; D Schilling; J Reindl; B Meyer; J Gempt; S Motov; F Alexander; J J Wilkens; J Schlegel; T E Schmid; S E Combs
Journal:  J Neurooncol       Date:  2018-06-08       Impact factor: 4.130

4.  Novel Surgical Approaches to High-Grade Gliomas.

Authors:  Fahid Tariq Rasul; Colin Watts
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

5.  Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

Authors:  Maxime S Heroux; Marla A Chesnik; Brian D Halligan; Mona Al-Gizawiy; Jennifer M Connelly; Wade M Mueller; Scott D Rand; Elizabeth J Cochran; Peter S LaViolette; Mark G Malkin; Kathleen M Schmainda; Shama P Mirza
Journal:  Physiol Genomics       Date:  2014-05-06       Impact factor: 3.107

6.  Real-time multi-modality imaging of glioblastoma tumor resection and recurrence.

Authors:  Shawn Hingtgen; Jose-Luiz Figueiredo; Christian Farrar; Matthias Duebgen; Jordi Martinez-Quintanilla; Deepak Bhere; Khalid Shah
Journal:  J Neurooncol       Date:  2012-12-16       Impact factor: 4.130

7.  Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.

Authors:  C Balaña; J Capellades; P Teixidor; I Roussos; R Ballester; M Cuello; A Arellano; R Florensa; R Rosell
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

8.  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Authors:  Thomas Reithmeier; Erika Graf; Tobias Piroth; Michael Trippel; Marcus O Pinsker; Guido Nikkhah
Journal:  BMC Cancer       Date:  2010-02-02       Impact factor: 4.430

9.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

10.  Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Authors:  Stefan Pursche; Eberhard Schleyer; Malte von Bonin; Gerhard Ehninger; Samir Mustafa Said; Roland Prondzinsky; Thomas Illmer; Yanfeng Wang; Christian Hosius; Zariana Nikolova; Martin Bornhäuser; Gregor Dresemann
Journal:  Curr Clin Pharmacol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.